Homeobox B8 (HOXB8) belongs to the HOX family and was essential to the development of colorectal carcinoma. Among the prevalent monoclonal antibodies for treating RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients, cetuximab stands out, but ...
Yunan Liang +5 more
doaj +1 more source
Theranostic Potential of EFNB2 for Cetuximab Resistance in Head and Neck Cancer. [PDF]
Chaudhary RK +4 more
europepmc +1 more source
Microenvironment plasticity confers cetuximab resistance [PDF]
openaire +2 more sources
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity. [PDF]
Zaryouh H +14 more
europepmc +1 more source
Objective: To investigate the underlying molecular mechanisms contributing to oral squamous cell carcinoma (OSCC) cell resistance to the epidermal growth factor receptor (EGFR) inhibitor. Materials and methods: OSCC cell lines HSC-2 and HSC-3 were assessed in vitro for drug treatment, cell viability, and gene expression and the online gene expression ...
Hua, Yang +11 more
openaire +1 more source
3-Bromopyruvate overcomes cetuximab resistance in human colorectal cancer cells by inducing autophagy-dependent ferroptosis. [PDF]
Mu M +6 more
europepmc +1 more source
IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner. [PDF]
Chen LJ +14 more
europepmc +1 more source
Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction. [PDF]
Jiang J +8 more
europepmc +1 more source
Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. [PDF]
PurposeGenomic alterations in blood-derived circulating tumor DNA (ctDNA) from patients with colorectal cancers were correlated with clinical outcomes.Patients and methodsNext-generation sequencing of ctDNA (54- to 73-gene panel) was performed in 94 ...
Fanta, Paul T +9 more
core +1 more source
Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) shows a limited clinical benefit for patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), due to the frequent occurrence of secondary ...
Valentin Van den bossche +29 more
doaj +1 more source

